Celaid Therapeutics Inc. has received notices of allowance in Japan for two core patents covering an albumin-free, serum-free medium and associated methods for expanding hematopoietic stem cells (HSCs), to which the company holds an exclusive license:
- WO2021/149799 A1 — “Serum-free medium and culturing method suited for culturing blood cells such as human hematopoietic stem cells.”
- WO2021/049617 A1 — “Albumin-free serum-free medium and albumin-free culturing method suited for culturing human hematopoietic stem cells.”
We are advancing patent protection globally, including in the United States and Europe. Celaid will continue to reinforce intellectual property protection for its foundational technologies worldwide.